Ruling on Sanofi-Aventis Case Coming Soon

A U.S. judge said on Tuesday that he would rule as soon as possible on a request to block the sale of a generic version of Sanofi-Aventis’ (SASY.PA) blood thinner drug being marketed by Novartis AG’s (NOVN.VX) Sandoz unit and Momenta Inc (MNTA.O).

Sanofi had argued that the FDA wrongly approved the generic medicine in July, stating that health regulators had failed to ensure that the generic version by Sandoz had the same active ingredient as its drug, known as Lovenox, which used to treat blood clots.  Sanofi sought a preliminary injunction blocking the FDA’s decision.

For further reading on the story, click here.

This entry was posted in Industry Updates. Bookmark the permalink.

Comments are closed.